# Myricitrin inhibits vascular adhesion molecule expression in TNF-α-stimulated vascular smooth muscle cells

LI-JIE YAN, HAI-TAO YANG, HONG-YAN DUAN, JIN-TAO WU, PENG QIAN, XIAN-WEI FAN and SHANLING WANG

Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China

Received December 22, 2015; Accepted June 20, 2017

# DOI: 10.3892/mmr.2017.7321

Abstract. Increased expression of adhesion molecules is thought to serve an important role in the pathogenesis of atherosclerosis. Myricitrin, a bioactive compound of Myrica cerifera, has been demonstrated to exhibit anti-atherogenic effects. However, the effect of myricitrin on the expression of adhesion molecules in vascular smooth muscle cells (VSMCs) remains unknown. Therefore, the aim of the present study was to evaluate the inhibitory effects of myricitrin on tumor necrosis factor- $\alpha$  $(TNF-\alpha)$ -induced expression of adhesion molecules in VSMCs in vitro. The results revealed that myricitrin inhibited the adhesion of human THP-1 monocyte cells to TNF-α-stimulated mouse MOVAS-1 VSMC cells, and reduced the expression of adhesion molecules in TNF-a-stimulated MOVAS-1 cells. In addition, myricitrin significantly inhibited the TNF-a-induced expression of nuclear factor (NF)-KB p65, and prevented the TNF- $\alpha$ -induced degradation of nuclear factor of  $\kappa$  light chain enhancer in B-cells inhibitor a. Furthermore, myricitrin inhibited the production of intracellular reactive oxygen species in TNF-α-stimulated MOVAS-1 cells. In conclusion, the results of the present study indicated that myricitrin inhibits the expression of vascular cell adhesion protein-1 and intercellular adhesion molecule-1 in TNF-α-stimulated MOVAS-1 cells potentially via the NF-kB signaling pathway. Therefore, myricitrin may be an effective pharmacological agent for the prevention or treatment of atherosclerosis.

# Introduction

Atherosclerosis is the most common type of coronary artery disease and the leading cause of morbidity and mortality worldwide (1). It is characterized by the accumulation of lipids

*Correspondence to:* Professor Shanling Wang, Department of Cardiology, Henan Provincial People's Hospital, 7 Weiwu Road, Zhengzhou, Henan 450003, P.R. China E-mail: wshlingzz@sina.com

*Key words:* atherosclerosis, myricitrin, adhesion molecule, vascular smooth muscle cells

in the arterial vessel wall (2). A number of studies have demonstrated that the expression of cell adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesionmolecule-1 (VCAM-1), is increased in vascular smooth muscle cells (VSMCs), leading to increased neointima or atherosclerotic lesion formation (3-5). In addition, the expression of adhesion molecules in vascular cells is affected by inflammatory cytokines, such as tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ) (6). Therefore, a promising therapeutic approach for the treatment of pathological inflammation may be to reduce the expression of adhesion molecules in VSMCs.

Myricitrin, a bioactive compound of Myrica cerifera, has been demonstrated to exhibit a number of pharmacological actions, including antinociceptive, anti-inflammatory, anticancer and anti-oxidative activities (7-9). Domitrović et al (10) reported that myricitrin significantly reduced the carbon tetrachloride-induced increase in cyclooxygenase-2 and TNF- $\alpha$  levels in the liver. In addition, a previous study demonstrated that myricitrin exhibits anti-atherogenic effects (11). Administration of myricitrin in vivo decreased the vascular wall thickness of the aortic arch in apolipoprotein E<sup>-/-</sup> mice, and myricitrin treatment significantly attenuated oxidized low-density lipoprotein-induced endothelial cell apoptosis (11). However, the effect of myricitrin on the expression of adhesion molecules in VSMCs remains unknown. Therefore, the aim of the present study was to evaluate the inhibitory effects of myricitrin on adhesion molecule expression induced by TNF- $\alpha$ in VSMCs in vitro.

# Materials and methods

*Cell culture*. The VSMC cell line MOVAS-1 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin (Sigma; Merck KGaA, Darmstadt, Germany), 100  $\mu$ g/ml streptomycin (Sigma; Merck KGaA), and 200 mM L-glutamine (Sigma; Merck KGaA) in a humidified 5% CO<sub>2</sub> atmosphere at 37°C. THP-1 cells (ATCC) were maintained in RPMI-1640 (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS, 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin in an incubator with a humidified atmosphere of 5% CO<sub>2</sub> at 37°C.

Cell adhesion assay. The cell adhesion assay was performed as previously described (12). Briefly, MOVAS-1 cells were plated in 96-well plates at a density of ~1x10<sup>4</sup> cells/well, which were then pretreated with varying concentrations (2.5, 5 and 10  $\mu$ M) of myricitrin (Sigma; Merck KGaA) for 2 h, followed by stimulation with or without TNF- $\alpha$  (10 ng/ml; Sigma; Merck KGaA) for 8 h. The media was removed from the wells and 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein-labeled (5  $\mu$ M; Sigma; Merck KGaA) THP-1 cells (1x10<sup>5</sup> cells/ml) in 0.2 ml medium were added to each well. Following incubation for 1 h at 37°C in 5% CO<sub>2</sub>, the wells were washed three times with 0.2 ml medium, and the number of adherent cells in 4 high power fields of view were observed using a Nikon Eclipse E600 fluorescence microscope at x100 magnification (Nikon Corporation, Tokyo, Japan).

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from MOVAS-1 cells (1x10<sup>4</sup> cells/well) with TRIzol reagent (Abcam, Cambridge, UK) according to the manufacturer's instructions. Total RNA (5  $\mu$ g) was reverse transcribed into cDNA using an oligo-(dT) primer and M-MLV reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) for qPCR analysis. qPCR was performed in a final volume of 10 µl, which consisted of 5 µl SsoFast<sup>™</sup> EvaGreen Supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA), 1 µl cDNA (1:50 dilution) and  $2 \mu l$  each of the forward and reverse primers (1 mM). The specific primers (Invitrogen; Thermo Fisher Scientific, Inc.) were as follows: VCAM-1 sense, 5'-CAAAGG TGGATCAGATTCAAG-3' and antisense, 5'-GGTGAGCAT TATCACCCAGAA-3'; ICAM-1 sense, 5'-CAAAGGTGGATC AGATTCAAG-3' and antisense, 5'-GGTGAGCATTATCAC CCAGAA-3'; GAPDH sense, 5'-CAAAGGTGGATCAGA TTCAAG-3' and antisense, 5'-GGTGAGCATTATCACCCA GAA-3'. The thermal cycling procedure was as follows: 95°C for 4 min, followed by 40 cycles of 95°C for 25 sec, 55°C for 30 sec and 72°C for 20 sec with 2 sec for plate reading, and melting curve analysis from 65 to 95°C. GAPDH was used as the control for normalizing gene expression. The relative quantification of the gene of interest was determined using the comparative  $\Delta Cq$  method (13).

Western blot analysis. MOVAS-1 cells (1x10<sup>6</sup> cells) were harvested, washed twice with phosphate-buffered saline, and lysed in radioimmunoprecipitation assay buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) containing 100 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% Triton X-100, 1 mM EDTA, 10 mM β-glycerophosphate, 2 mM sodium vanadate and protease inhibitors (Cell Signaling Technology, Inc.) on ice for 10 min. Following 15 min, 0.5% Nonidet P (NP)-40 (Mairybio; Beijing Minhai Biotechnology Co., Ltd., Beijing, China) was added to lyse the cells, which were vortexed for 10 sec. Then, cytosolic cell extracts were obtained following centrifugation at 1,500 x g for 10 min at 4°C. The collected nuclei were re-suspended in 50 µl of Buffer C [20 mM HEPES (pH 7.9), 1.5 mM MgCl<sub>2</sub>, 420 mM NaCl, 0.2 mM EDTA, 25% v/v glycerol, 0.5 mM PMSF and Protease Inhibitor Cocktail] and were then incubated on ice for 20 min with intermittent agitation. Nuclear cell extracts were obtained following centrifugation for 10 min at 13,000 x g and 4°C. Equal amounts (30 µg) of



Figure 1. Inhibition of THP-1 cell adhesion to TNF- $\alpha$ -stimulated MOVAS-1 cells by myricitrin. Confluent MOVAS-1 cells were pretreated for 2 h with 0, 2.5, 5 or 10  $\mu$ M myricitrin. The cells were then washed twice with medium and incubated with TNF- $\alpha$  (10 ng/ml) for 8 h. The 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein-labeled THP-1 cells were added to the MOVAS-1 cell monolayer and allowed to adhere for 1 h. Adherent THP-1 to MOVAS-1 cells were observed under a fluorescence microscope at x100 magnification. All experiments were repeated at least three times. Data are presented as the mean  $\pm$  standard deviation. \*P<0.05 vs. the untreated control group, \*P<0.05 vs. the TNF- $\alpha$ -only treated group. TNF- $\alpha$ , tumor necrosis factor- $\alpha$ .

protein sample were separated using a 10% SDS-PAGE gel and then electrotransferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking in Tris-buffered saline buffer (50 mmol/l NaCl, 10 mmol/l Tris, pH 7.4) containing 5% non-fat milk for 1 h at room temperature, the membranes were then incubated with the appropriate primary antibodies against VCAM-1 (1:3,000; cat. no. sc-13160), ICAM-1 (1:3,000; cat. no. sc-8439), nuclear factor (NF)-kB p65 (1:2,000; cat. no. sc-8008), nuclear factor of  $\kappa$  light chain gene enhancer in B-cells inhibitor  $\alpha$  (I $\kappa$ B $\alpha$ ; 1:2,500; cat. no. sc-1643) and GAPDH (1:3,000; cat. no. sc-47724) at 4°C overnight, followed by incubation with a horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (1:3,000; cat. no. sc-2005; all from Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 1 h at room temperature. The membranes were exposed and visualized using enhanced chemiluminescence reagent (Thermo Fisher Scientific, Inc.). Densitometry was performed using Gel-Pro Analyzer software version 4.0 (Media Cybernetics, Inc., Rockville, MD, USA).

Measurement of intracellular reactive oxygen species (ROS) accumulation. Intracellular ROS levels were measured using dichlorofluorescein diacetate (DCFH-DA; Sigma-Aldrich; Merck KGaA, ) staining. Briefly, MOVAS-1 cells (1x10<sup>4</sup> cells/well) treated with myricitrin in the presence or absence of TNF- $\alpha$  (as described in the *Cell adhesion assay* section) were incubated with 5  $\mu$ M DCFH-DA for 30 min at 37°C in the dark, and were then washed with serum-free medium three times. The fluorescence intensity was measured at an excitation and emission wavelength of 485 and 520 nm, respectively, using a fluorescence spectrophotometer (Infinite M1000; Tecan Austria GmbH, Grödig, Austria). The ROS level was expressed as units of fluorescence.

Statistical analysis. The results were analyzed using SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA) and data are expressed as the mean  $\pm$  standard deviation. Statistical



Figure 2. Effect of myricitrin on adhesion molecule expression in TNF- $\alpha$ -stimulated MOVAS-1 cells. MOVAS-1 cells were preincubated with varying concentrations (0, 2.5, 5 and 10  $\mu$ M) of myricitrin for 2 h and stimulated with TNF- $\alpha$  (10 ng/ml) for 8 h. (A) VCAM-1 and (B) ICAM-1 mRNA expression was determined by reverse transcription-quantitative polymerase chain reaction analysis. (C) VCAM-1 and ICAM-1 protein expression was determined by western blot analysis. All experiments were repeated at least three times. Data are presented as mean  $\pm$  standard deviation. \*P<0.05 vs. the untreated control group, \*P<0.05 vs. the TNF- $\alpha$ -only treated group. TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1.

significance was assessed by one-way analysis of variance followed by a Tukey post hoc test. P<0.05 was considered to indicate a statistically significant difference.

## Results

Myricitrin inhibited the adhesion of THP-1 cells to TNF- $\alpha$ -stimulated MOVAS-1 cells. The effect of myricitrin on the adhesion of THP-1 cells to MOVAS-1 cells in response to TNF- $\alpha$  was first evaluated. As shown in Fig. 1, treatment of confluent MOVAS-1 cells with TNF- $\alpha$  for 8 h resulted in a 2.8-fold increase in the adhesion of THP-1 monocytic cells when compared with untreated MOVAS-1 cells (P<0.05). By contrast, pretreatment with myricitrin significantly inhibited the adhesion of THP-1 cells to TNF- $\alpha$ -stimulated MOVAS-1 cells in a dose-dependent manner (2.5  $\mu$ M, P<0.05; 5  $\mu$ M, P<0.05; 10  $\mu$ M, P<0.05; Fig. 1).

Myricitrin inhibited the expression of adhesion molecules in TNF-a-stimulated MOVAS-1 cells. The increased expression of adhesion molecules is thought to serve an important role in the pathogenesis of atherosclerosis (4). Therefore, the present study investigated the effect of myricitrin on the expression of adhesion molecules in MOVAS-1 cells in response to TNF-a treatment. The RT-qPCR analysis results revealed that TNF- $\alpha$  significantly increased the mRNA expression levels of VCAM-1 and ICAM-1 in MOVAS-1 cells when compared with untreated controls. However, myricitrin significantly suppressed the mRNA expression levels of VCAM-1 and ICAM-1 in TNF- $\alpha\text{-stimulated}$ MOVAS-1 cells (VCAM-1, P<0.05; ICAM-1, P<0.05; Fig. 2A and B). In addition, myricitrin significantly suppressed the protein expression levels of VCAM-1 and ICAM-1 in TNF-α-stimulated MOVAS-1 cells (P<0.05 and P<0.05, respectively; Fig. 2C).



Figure 3. Effect of myricitrin on NF- $\kappa$ B activation and I $\kappa$ B $\alpha$  degradation in TNF- $\alpha$ -stimulated MOVAS-1 cells. MOVAS-1 cells were preincubated with 0, 2.5, 5 or 10  $\mu$ M of myricitrin for 2 h, before they were treated with TNF- $\alpha$  for 8 h. (A) The nuclear level of NF- $\kappa$ B p65 was detected by western blotting to analyze the translocation of NF- $\kappa$ B. (B) I $\kappa$ B $\alpha$  degradation as determined by western blot analysis. All experiments were repeated at least three times. Data are presented as the mean  $\pm$  standard deviation. \*P<0.05 vs. the untreated control group, \*P<0.05 vs. the TNF- $\alpha$ -only treated group. NF- $\kappa$ B, nuclear factor  $\kappa$ B; I $\kappa$ Ba, nuclear factor of  $\kappa$  light chain gene enhancer in B-cells inhibitor  $\alpha$ ; TNF- $\alpha$ , tumor necrosis factor  $\alpha$ .

Myricitrin suppressed TNF-α-induced NF-κB activation in MOVAS-1 cells. NF-κB has been reported to serve a critical role in the regulation of adhesion molecule expression (14). Therefore, the present study investigated the effects of myricitrin on NF-κB activation in MOVAS-1 cells in response to TNF-α treatment. As indicated in Fig. 3, TNF-α significantly increased NF-κB p65 protein expression and IκBα degradation (NF-κB, P<0.05; IκBα, P<0.05). However, myricitrin pretreatment significantly prevented the TNF-α-induced increase in NF-κB p65 and the TNF-α-induced degradation of IκBα in



Figure 4. Effect of myricitrin on the production of ROS in TNF- $\alpha$ -stimulated MOVAS-1 cells. MOVAS-1 cells were treated with 0, 2.5, 5 or 10  $\mu$ M myricitrin for 2 h followed by stimulation with TNF- $\alpha$  (10 ng/ml) for 8 h. ROS production was measured by fluorescence spectrophotometry. All experiments were repeated at least three times. Data are presented as the mean  $\pm$  standard deviation. \*P<0.05 vs. the untreated control group, \*P<0.05 vs. the TNF- $\alpha$ -only treated group. ROS, reactive oxygen species; TNF- $\alpha$ , tumor necrosis factor  $\alpha$ .

MOVAS-1 cells in a dose-dependent manner (NF- $\kappa$ B, P<0.05 at 2.5, 5 and 10  $\mu$ M myricitrin; I $\kappa$ B $\alpha$ , P<0.05 at 2.5, 5 and 10  $\mu$ M myricitrin; Fig. 3).

Myricitrin inhibited ROS production in TNF- $\alpha$ -stimulated MOVAS-1 cells. ROS is involved in the development of atherosclerosis (15). Therefore, the present study examined the effect of myricitrin on ROS production in MOVAS-1 cells in response to TNF- $\alpha$ . As shown in Fig. 4, treatment with TNF- $\alpha$  significantly increased the production of ROS when compared to that of the untreated control cells (P<0.05). By contrast, pretreatment with myricitrin significantly inhibited TNF- $\alpha$ -induced ROS production in MOVAS-1 cells in a dose-dependent manner (2.5  $\mu$ M, P<0.05; 5  $\mu$ M, P<0.05; 10  $\mu$ M, P<0.05; Fig. 4).

## Discussion

To the best of the authors' knowledge, the present study is the first to delineate the effects of myricitrin on the expression of adhesion molecules in TNF- $\alpha$ -stimulated MOVAS-1 cells. The results indicated that myricitrin inhibits the adhesion of THP-1 cells to TNF- $\alpha$ -stimulated MOVAS-1 cells, as well as the expression of adhesion molecules. The underlying mechanism may involve the NF- $\kappa$ B signaling pathway.

Leukocyte adhesion to VSMCs during atherosclerotic progression is primarily mediated by cell adhesion molecules, such as VCAM-1 and ICAM-1 (16). It has been demonstrated that VCAM-1 and ICAM-1 are expressed by VSMCs and are prominent in the fibrous caps of advanced atherosclerotic plaques (17). In addition, a number of studies have reported increased expression of VCAM-1 and ICAM-1 in coronary atherosclerotic tissues (18,19). Furthermore, inflammatory cytokines, such as interleukin-1 $\beta$  and TNF- $\alpha$ , may induce the expression of VCAM-1 and ICAM-1 in VSMCs (20-22). In accordance with previous reports, the present study demonstrated that TNF- $\alpha$  significantly increased the adhesion of

THP-1 cells to MOVAS-1 cells and the expression of VCAM-1 and ICAM-1 in MOVAS-1 cells. By contrast, myricitrin inhibited the adhesion of THP-1 cells to TNF- $\alpha$ -stimulated MOVAS-1 cells, as well as the expression of VCAM-1 and ICAM-1. These results indicate that myricitrin may exhibit an inhibitory effect on the expression of adhesion molecules in TNF- $\alpha$ -stimulated MOVAS-1 cells.

The NF- $\kappa$ B signaling pathway serves a critical role in the regulation of adhesion molecule expression (23,24). Translocation of NF- $\kappa$ B to the nucleus is preceded by the phosphorylation, ubiquitination and proteolytic degradation of  $I\kappa B\alpha$  (25). It has been reported that activation of the NF-kB transcription factor by TNF- $\alpha$  is required for the transcriptional activation of muscle cell adhesion molecules (26,27). Furthermore, a previous study reported that oral treatment with myricitrin induced anti-inflammatory effects in dextran sulfate sodium-induced acute colitis in mice by inhibiting Akt/phosphatidylinositol-3 kinase-dependent phosphorylation and the NF-KB signaling pathway (28). In addition, myricitrin was able to prevent the formation of advanced glycation end products by suppressing NF-KB activation and translocation triggered by methylglyoxal in SH-SY5Y cells (29). Similarly, myricitrin pretreatment prevented NF-kB p65 activation and IkBa degradation in TNF-a-stimulated MOVAS-1 cells in the present study. Therefore, these data indicate that the inhibitory effect of myricitrin on the expression of adhesion molecules may be mediated, in part, through suppression of the NF-KB signaling pathway.

ROS, which are synthesized by nicotinamide adenine dinucleotide phosphate oxidase, serve as secondary messengers that activate a number of signaling pathways, including the NF- $\kappa$ B pathway (30). Activation of these signaling cascades leads to the induction of various genes that serve critical roles in the development of atherosclerosis (31). In addition, it has been reported that TNF- $\alpha$  induces ROS production in VSMCs (20,32,33). The present study demonstrated that TNF- $\alpha$  significantly increased the production of ROS in MOVAS-1 cells. By contrast, pretreatment with myricitrin significantly inhibited ROS production in a concentration-dependent manner. These results indicate that myricitrin may inhibit the activation of NF- $\kappa$ B via suppression of ROS production in TNF- $\alpha$ -stimulated MOVAS-1 cells.

In conclusion, myricitrin inhibited the expression of VCAM-1 and ICAM-1 in TNF- $\alpha$ -stimulated MOVAS-1 cells potentially via the NF- $\kappa$ B signaling pathway. Therefore, myricitrin may be an effective pharmacological agent for the prevention or treatment of atherosclerosis.

#### References

- Zernecke A, Shagdarsuren E and Weber C: Chemokines in atherosclerosis: An update. Arterioscler Thromb Vasc Biol 28: 1897-1908, 2008.
- 2. Munro J and Cotran R: The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest 58: 249-261, 1988.
- Tschoepe D: Adhesion molecules influencing atherosclerosis. Diabetes Res Clin Pract 30 (Suppl): S19-S24, 1996.
- Galkina E and Ley K: Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 27: 2292-2301, 2007.
- O'Brien KD, McDonald TO, Chait A, Allen MD and Alpers CE: Neovascular expression of E-selectin, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93: 672-682, 1996.
- Huo Y and Ley K: Adhesion molecules and atherogenesis. Acta Physiol Scand 173: 35-43, 2001.

- Wang Y, Chen P, Tang C, Wang Y, Li Y and Zhang H: Antinociceptive and anti-inflammatory activities of extract and two isolated flavonoids of *Carthamus tinctorius* L. J Ethnopharmacol 151: 944-950, 2014.
- Xu R, Zhang Y, Ye X, Xue S, Shi J, Pan J and Chen Q: Inhibition effects and induction of apoptosis of flavonoids on the prostate cancer cell line PC-3 in vitro. Food Chem 138: 48-53, 2013.
- 9. Huang Q, Gao B, Wang L, Hu YQ, Lu WG, Yang L, Luo Z-J and Liu J: Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol 280: 550-560, 2014.
- Domitrović R, Rashed K, Cvijanović O, Vladimir-Knežević S, Škoda M and Višnić A: Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chem Biol Interact 230: 21-29, 2015.
- Qin M, Luo Y, Meng XB, Wang M, Wang HW, Song SY, Ye JX, Pan RL, Yao F, Wu P, *et al*: Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: An insight into PI3K/Akt activation and STAT3 signaling pathways. Vascul Pharmacol 70: 23-34, 2015.
- 12. Chen C, Chou C, Sun Y and Huang W: Tumor necrosis factor alpha-induced activation of downstream NF-kappaB site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion. Involvement of PKCalpha, tyrosine kinase, and IKK2, but not MAPKs, pathway. Cell Signal 13: 543-553, 2001.
- 13. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-tie quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
- Baker RG, Hayden MS and Ghosh S: NF-κB, inflammation, and metabolic disease. Cell Metab 13: 11-22, 2011.
- Cheng JC, Cheng HP, Tsai IC and Jiang MJ: ROS-mediated downregulation of MYPT1 in smooth muscle cells: A potential mechanism for the aberrant contractility in atherosclerosis. Lab Invest 93: 422-433, 2013.
- 16. Rains JL and Jain SK: Hyperketonemia increases monocyte adhesion to endothelial cells and is mediated by LFA-1 expression in monocytes and ICAM-1 expression in endothelial cells. Am J Physiol Endocrinol Metab 301: E298-E306, 2011.
- Libby P and Li H: Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J Clin Invest 92: 538-539, 1993.
- Yang PY, Rui YC, Lu L, Li TJ, Liu SQ, Yan HX and Wang HY: Time courses of vascular endothelial growth factor and intercellular adhesion molecule-1 expressions in aortas of atherosclerotic rats. Life Sci 77: 2529-2539, 2005.
- Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D and Kyriakopoulos A: The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171: 223-229, 1993.
- 20. Kim JY, Park HJ, Um SH, Sohn EH, Kim BO, Moon EY, Rhee DK and Pyo S: Sulforaphane suppresses vascular adhesion molecule-1 expression in TNF-α-stimulated mouse vascular smooth muscle cells: Involvement of the MAPK, NF-κB and AP-1 signaling pathways. Vascul Pharmacol 56: 131-141, 2012.
- 21. Choi KW, Park HJ, Jung DH, Kim TW, Park YM, Kim BO, Sohn EH, Moon EY, Um SH and Rhee DK: Inhibition of TNF-α-induced adhesion molecule expression by diosgenin in mouse vascular smooth muscle cells via downregulation of the MAPK, Akt and NF-κB signaling pathways. Vascul Pharmacol 53: 273-280, 2010.
- 22. Hakonarson H, Halapi E, Whelan R, Gulcher J, Stefansson K and Grunstein MM: Association between IL-1beta/TNF-alphainduced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle. Am J Respir Cell Mol Biol 25: 761-771, 2001.
- 23. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, Khew-Goodall Y, Bert AG, Barter PJ and Vadas MA: Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 95: 14196-14201, 1998.
- 24. Zhang WJ and Frei B: Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 15: 2423-2432, 2001.
- 25. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
- 26. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D and Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9: 899-909, 1995.

- 27. Beg AA, Finco T, Nantermet PV and Baldwin AS Jr: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: A mechanism for NF-kappa B activation. Mol Cell Biol 13: 3301-3310, 1993.
- 28. Schwanke RC, Marcon R, Meotti FC, Bento AF, Dutra RC, Pizzollatti MG and Calixto JB: Oral administration of the flavonoid myricitrin prevents dextran sulfate sodium-induced experimental colitis in mice through modulation of PI3K/Akt signaling pathway. Mol Nutr Food Res 57: 1938-1949, 2013.
- 29. Wang YH, Yu HT, Pu XP and Du GH: Myricitrin alleviates methylglyoxal-induced mitochondrial dysfunction and AGEs/RAGE/NF-κB pathway activation in SH-SY5Y cells. J Mol Neurosci 53: 562-570, 2014.
- 30. Zhang GG, Bai YP, Chen MF, Shi RZ, Jiang DJ, Fu QM, Tan GS and Li YJ: Asymmetric dimethylarginine induces TNF-alpha production via ROS/NF-kappaB dependent pathway in human monocytic cells and the inhibitory effect of reinioside C. Vascul Pharmacol 48: 115-121, 2008.
- Griendling KK, Sorescu D, Lassègue B and Ushio-Fukai M: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000.
- Zhang HS and Wang SQ: Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-alpha (TNF-alpha)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species. J Mol Cell Cardiol 41: 138-148, 2006.
  Wang Z, Zhang Y, Li Y, Banerjee S, Liao J and Sarkar FH:
- 33. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J and Sarkar FH: Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5: 483-493, 2006.